Tranylcypromine Hemisulfate – MAOI Antidepressant

Tranylcypromine Hemisulfate: Chemical and Pharmacological Aspects of a Classical MAOI Antidepressant

1. Introduction

Tranylcypromine is an antidepressant belonging to the class of monoamine oxidase inhibitors (MAOIs), first described in the mid‑20th century. Despite the emergence of newer antidepressant classes (SSRIs, SNRIs, atypical antipsychotics, etc.), tranylcypromine retains clinical significance in the treatment of treatment‑resistant depression and is also used in some cases of anxiety and phobic disorders. Its clinical use is limited by the risk of hypertensive crisis (the "cheese effect") upon consumption of tyramine‑rich foods and by other drug‑food and drug‑drug interactions.

2. Nomenclature and Chemical Composition

Chemical name: (±)-trans-2‑Phenylcyclopropylamine hemisulfate (also described as trans‑2‑phenylcyclopropanamine hemisulfate)

Molecular formula:

• Free base: C₉H₁₁N

• Hemisulfate salt: (C₉H₁₁N)₂·H₂SO₄ (C₁₈H₂₄N₂O₄S)

Molecular weight: 364.46–364.5 g/mol (hemisulfate salt); 182.23 g/mol (as C₉H₁₁N·½H₂SO₄)

CAS number: 13492-01-8

MDL number: MFCD00079222

Trade names: Parnate® (in various countries)

Purity: Typically ≥98%

3. Physicochemical Properties

Appearance: White to off‑white crystalline powder

Solubility: Soluble in water and alcohol; poorly soluble in non‑polar organic solvents.

Chemical stability: Stable under normal storage conditions in a dry, tightly sealed container, protected from light and moisture.

4. Mechanism of Action

Tranylcypromine acts as a non‑selective, irreversible inhibitor of both monoamine oxidase A (MAO‑A) and monoamine oxidase B (MAO‑B). MAO is the enzyme responsible for the oxidative deamination of neurotransmitters such as dopamine, norepinephrine, and serotonin. By irreversibly binding to the enzyme’s flavin adenine dinucleotide (FAD) cofactor, tranylcypromine prevents the breakdown of these monoamines, leading to their accumulation in the synaptic cleft and enhanced neurotransmission. The antidepressant effect is presumed to result from this potentiation of monoamine neurotransmitter activity in the central nervous system.

In addition to MAO inhibition, tranylcypromine hemisulfate is also a lysine‑specific demethylase 1 (LSD1) inhibitor, which has been investigated in research contexts, including cancer and endometriosis models.

5. Pharmacokinetics

Absorption: Tranylcypromine is rapidly absorbed after oral administration, with peak plasma levels attained within 0.67 to 3.5 hours. Absorption may be biphasic in some individuals.

Half‑life: The pharmacokinetic half‑life (t₁/₂) is short, approximately 1.5 to 3.15 hours (mean ~2 hours). However, because MAO inhibition is irreversible, the pharmacodynamic half‑life is much longer – approximately one week – as new enzyme must be synthesized to restore MAO activity.

Metabolism: Tranylcypromine undergoes extensive metabolism, including side‑chain breakdown and conjugation reactions.

Excretion: Primarily excreted in urine within 24 hours; some drug is excreted in feces via the biliary tract.

6. Clinical Indications

Tranylcypromine sulfate tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. It is considered a second‑ or third‑line agent for treatment‑resistant depression. MAOIs, including tranylcypromine, appear particularly effective in treating major depressive disorder with atypical features.

7. Dosing and Administration

Treatment typically begins with a low dose (e.g., 20 mg/day) with gradual titration based on clinical response. The maximum daily dose may reach 30–60 mg, though safety and tolerability at higher doses require careful evaluation. Dose adjustments are necessary in elderly, debilitated, or comorbid patients.

8. Adverse Effects and Safety Considerations

Common side effects: Insomnia, dizziness, headache, dry mouth, constipation, orthostatic hypotension, tremor, and drowsiness.

Serious risks:

• Hypertensive crisis ("cheese effect"): Consumption of tyramine‑rich foods (aged cheeses, cured meats, fermented beverages, yeast extracts) can cause a rapid, dangerous rise in blood pressure due to unopposed tyramine entering the systemic circulation.

• Serotonin syndrome: Risk increased when combined with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, etc.).

• Suicidality: May cause worsening of depression or emergence of suicidal thoughts, particularly early in treatment or after dose changes.

Contraindications: Not approved for use in pediatric patients.

9. Drug Interactions

Concurrent use with SSRIs (especially fluoxetine) is contraindicated due to serotonin syndrome risk; a washout period is required. Combination with tricyclic antidepressants increases the risk of severe hypertension and cardiovascular complications. Sympathomimetics (pseudoephedrine, phenylephrine) may cause dangerous blood pressure elevations. Meperidine and certain other opioids can lead to serious respiratory and CNS complications.

10. Contemporary Use and Research Perspectives

Tranylcypromine remains a valuable reserve antidepressant for patients who do not respond to other classes. Research continues into its LSD1 inhibitory properties, with potential applications in oncology and other fields. Future directions include the development of more selective MAO inhibitors and formulations with improved safety profiles.

11. Conclusion

Tranylcypromine hemisulfate (CAS 13492-01-8) is a classical, non‑selective, irreversible MAOI with a well‑established role in the treatment of treatment‑resistant depression. Its clinical use requires strict dietary restrictions, careful monitoring for drug interactions, and patient education regarding the risks of hypertensive crisis and serotonin syndrome. Despite the availability of newer antidepressants, tranylcypromine retains an important niche in psychiatry as a reserve agent for patients who have failed to respond to other therapies. Ongoing research into its LSD1 inhibitory activity may reveal additional therapeutic applications.

This article is for informational purposes only and does not constitute medical advice. The use of any pharmaceutical agent should only be conducted under the supervision of a qualified healthcare professional and in accordance with applicable laws and regulations.